Earnings Preview: AVDL to Report Financial Results Pre-market on November 12
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
Loss-Making Avadel Pharmaceuticals Plc (NASDAQ:AVDL) Expected To Breakeven In The Medium-Term
Avadel Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Raises Target Price to $30
Express News | Avadel Pharmaceuticals PLC - Lumryz Approval Upheld Based on Clinical Superiority
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Avadel Pharmaceuticals and Nference Announce Publication of Real-World Data in Sleep Advances
H.C. Wainwright Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Maintains Target Price $27
Avadel Pharmaceuticals Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Craig-Hallum Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating
Craig-Hallum Remains a Buy on Avadel Pharmaceuticals (AVDL)
Oppenheimer Maintains Avadel Pharmaceuticals(AVDL.US) With Buy Rating, Maintains Target Price $29
Analysts Are Bullish on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL), Rani Therapeutics Holdings (RANI)
Express News | Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target
Avadel Gets Expanded FDA OK of Lumryz for Use in Children
Avadel Pharmaceuticals Announces FDA Approval of SNDA for LUMRYZ
Express News | Avadel Pharmaceuticals PLC - Lumryz Granted Orphan Drug Exclusivity Through October 16, 2031
No Data
No Data